26 Sep 2019 12:04
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of PDMR Dealing
London, September 26, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on September 25, 2019, Alastair MacKinnon, Chief Medical Officer of Mereo, purchased 3313 Ordinary Shares at a price of GBP0.60 per share.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1 | Details of the person discharging managerial responsibilities | |||||
a) | Name | Alastair MacKinnon | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Medical Officer | ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc | ||||
b) | LEI | 213800U8JQHIJOS5AS09 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
| ||||
b) | Nature of the transaction | PURCHASE | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | Aggregated volume: 3313 Aggregated price: GBP0.60 | ||||
e) | Date of the transaction | 2019-09-25 | ||||
f) | Place of the transaction | AIMX | ||||